SecBot SecBot
6-K ·Filed Jun 29, 2026

AZN

ASTRAZENECA PLC
BULLISH
Impact 6/10
Horizonweeks Processed4mo ago SEC0001654954-26-006239
Notable filing: 6-K
Actionable Insight ▲ Bullish

The CHMP recommendation de-risks EU approval and supports Datroway's commercial trajectory as a multi-indication ADC. Monitor the EMA's final approval decision within ~2-3 months and the pace of EU country-level pricing/reimbursement access. With US approval in TNBC and HR+/HER2- breast cancer already secured, the EU expansion adds a high-volume market, further upside catalysts include the ongoing reviews in China/Japan and the TROPION-Lung01/lung cancer data.

DirectionBullish
Confidencehigh
Horizonweeks

Drug in focus

AZN drug pipeline →

Datroway

▲ Bullish Named in this 6-K
Impact
Phase
Approved
Time to market
Already approved and marketed (first US approval Jan 2025, three indications now approved)
Next catalyst
None dated

What to watchWatch AstraZeneca's quarterly earnings for Datroway sales growth as a commercial read-through. The ongoing TROPION-Lung trials (first-line NSCLC) could expand the addressable market materially if positive, but those readouts have no firm dates yet. The main competitive risk is Gilead's Trodelvy, but Datroway appears to have an efficacy and dosing edge.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$190.95
T+0 close · Jun 29, 2026 · via day close
Latest settled
−11.83%
T+60 · $168.37
Vs SPY
−16.21%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 29 $190.95entry
  2. T+1 · 5mo ago −0.70%α −1.48% · $189.62
  3. T+5 · 4mo ago −0.41%α −1.80% · $190.16
  4. T+20 · 4mo ago −11.36%α −11.08% · $169.26
  5. T+60 · 8w ago −11.83%α −16.21% · $168.37
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca's Datroway (datopotamab deruxtecan) received a positive CHMP opinion recommending EU approval as 1st-line monotherapy for metastatic triple-negative breast cancer patients ineligible for immunotherapy, based on the TROPION-Breast02 Phase III trial showing a 5.0-month overall survival benefit vs chemotherapy. If approved, Datroway would become the first TROP2-directed ADC in the EU with a demonstrated OS benefit in this frontline setting, expanding its market beyond the existing US approval (May 2026) and HR+/HER2- breast cancer approvals in 40+ countries. The recommendation is a material pipeline catalyst that supports Datroway's peak sales trajectory in a large addressable EU market (estimated ~83,000 annual TNBC diagnoses).

Key Facts

  • Datroway recommended for EU approval by CHMP as 1st-line TNBC monotherapy for patients not candidates for PD-1/PD-L1 inhibitor therapy.
  • Recommendation based on TROPION-Breast02 Phase III trial showing statistically significant 5.0-month median OS improvement (23.7 vs 18.7 months; HR 0.79; p=0.0291).
  • Datroway reduced risk of disease progression or death by 43% (HR 0.57; p<0.0001) vs chemotherapy, with ORR 62.5% vs 29.3%.
  • Already approved in the US for this TNBC indication (May 2026) and in HR+/HER2- breast cancer in 40+ countries worldwide.
  • Additional regulatory reviews underway in China, Japan, Australia, Canada, Singapore, and Switzerland under Project Orbis.
  • EU represents ~83,000 annual TNBC diagnoses; ~70% of metastatic TNBC patients are not candidates for immunotherapy per filing.

Financial Impact

Positive recommendation expands Datroway's addressable market to the EU for first-line TNBC, a high-value indication with significant unmet need; the trial demonstrated a clinically meaningful 5-month survival benefit that supports premium pricing and adoption versus traditional chemotherapy.

revenueeps

Risk Factors

  • Final EMA approval may include restrictive label language or require confirmatory data.
  • Competition from Gilead's Trodelvy (sacituzumab govitecan) and emerging TROP2 ADCs could limit market share.
  • Pricing and reimbursement negotiations across EU member states may delay revenue ramp.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-006239
Document: 0001654954-26-006239-index-headers.html0001654954-26-006239
Document: 0001654954-26-006239-index.html0001654954-26-006239
Document: 0001654954-26-006239.txt0001654954-26-006239

Track record

77 reports on AZN

Performance horizon

19 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 29 of 37 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
  5. Nov 4, 202611d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Tue (17h 10m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026